Full-Time
Junior Data Governance Analyst
Updated on 8/1/2026
Medpace
5,001-10,000 employees
Global CRO delivering full-service clinical trials
No salary listed
Cincinnati, OH, USA
In Person
Office-based environment with occasional work from home available for eligible positions after training.
 Data & Analytics (1) |
|---|
Get referred to Medpace
See people who can refer or advise you
- A Bachelor's Degree in Business, Information Systems, Engineering, Computer Science, Business Analytics, or a related field is required.
- Requires 0-3 years of experience as a business systems analyst or developing business intelligence reports.
- Must be able to identify key process steps, strategies, and effort needed to achieve an outcome.
- Must be able to follow processes exactly and identify outliers in data or processes.
- Must be able to break problems into smaller pieces and isolate root causes.
- Must be able to tailor communication style to the audience and provide appropriate project-status updates.
- Must be able to translate business needs into concise requirement documents.
- Establish and maintain governance processes for business intelligence reports, automated workflows, micro applications, and artificial intelligence solutions.
- Work with business partners and developers to define processes for creating, reviewing, and releasing data solutions.
- Operate as a trusted business partner and bridge between business stakeholders and developers.
- Apply process control, problem-solving, communication, and attention to detail to streamline the governance process.
- Ensure the quality of data products while maintaining delivery speed.
- Develop and refine project management skills with a focus on Agile-Scrum methods.
- Help establish the foundational structure for governing the products produced by the Medpace Analytics Business Intelligence team.
Medpace is a global Contract Research Organization that provides end-to-end clinical development services for pharmaceutical, biotechnology, and medical device leaders. It runs Phase I–IV trials from study design through regulatory submissions, monitoring, data management, statistics, medical writing, and final reporting. A unique feature is ownership of integrated laboratories—global central labs, a bioanalytical lab, and imaging/ECG core labs—that streamline workflows and ensure data consistency. Its goal is to help sponsors bring therapies to market efficiently by coordinating all trial activities under a physician-led, scientifically driven team.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cincinnati, Ohio
Founded
1992
Get referred to Medpace
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 23, 2026 Q2 revenue reached $707.3 million, up 17.2%, beating estimates.
- Management raised 2026 revenue guidance to $2.805-$2.885 billion after 1.13x Q2 book-to-bill.
- Backlog reached $3.014 billion in Q2 2026, and headcount grew 7.3% to 6,479.
What critics are saying
- Durbin v. Medpace in S.D. Ohio alleges cancellation-rate and book-to-bill misstatements on February 9, 2026.
- Biopharma client funding remains Medpace's choke point; sponsor freezes quickly cut trials and bookings.
- Flat one-year revenue expectations in July 2026 signal a near-term demand slowdown after the beat.
What makes Medpace unique
- Founder-led, physician-run CRO, with August Troendle still CEO and Chairman in August 2026.
- Medpace owns central labs, bioanalytical, imaging, and ECG core labs, reducing vendor handoffs.
- It targets small and mid-sized biopharma, a neglected niche versus Big Pharma-focused CROs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Unlimited Paid Time Off
Competitive Compensation and Benefits Package
Employee Health and Wellness Initiatives
Hybrid Work Options
Structured Career Paths with Opportunities for Professional Growth
Growth & Insights and Company News
6 month growth
↑ 11%1 year growth
↑ 11%2 year growth
↑ 11%Medpace reported second-quarter revenue of $707.3 million, exceeding analyst estimates of $689.7 million and marking 17.2% year-on-year growth. The clinical research company's GAAP profit of $4.25 per share beat consensus estimates by 6.6%. The company raised its full-year revenue guidance to $2.85 billion at the midpoint, up from $2.81 billion previously. Full-year EPS guidance of $17.60 at the midpoint came in 3.9% above analyst expectations. Medpace's stock jumped 18.6% following the results. The company's adjusted EBITDA of $153.4 million also exceeded estimates, delivering a 21.7% margin. Despite the strong performance, analysts expect revenue to remain flat over the next 12 months, suggesting potential demand challenges ahead.
Clinical research company Medpace Holdings will report its second-quarter earnings on Wednesday after market hours. The market expects Medpace's revenue to grow 14.3% year on year this quarter, in line with the 14.2% increase it recorded in the same quarter last year. In the previous quarter, Medpace reported revenues of $706.6 million, up 26.5% year on year, beating analysts' expectations. The company also exceeded EPS estimates, though its full-year EPS guidance aligned with analysts' forecasts. Analysts covering the company have generally reconfirmed their estimates over the last 30 days. Medpace shares have risen 15.8% over the past month, outperforming the life sciences tools and services segment average of 9.9%.
Turtle Creek Asset Management added Medpace Holdings, Inc. (NASDAQ:MEDP) to its portfolio in Q1 2026, citing the clinical research organisation's differentiated strategy. The company focuses on small and mid-sized biopharma companies with full-service offerings, whilst competitors mainly serve Big Pharma with lower-margin work. Medpace's clinician-led model employs full-time MDs and PhDs to develop expertise in complex therapeutic areas. The founder-run company has demonstrated strong growth and cash flow generation. Its capital allocation approach is notably opportunistic, accumulating cash when shares are expensive and repurchasing aggressively when undervalued—buying back nearly 10% of outstanding shares last year. In Q1 2026, Medpace reported revenue of $706.6 million, up 26.5% year-over-year. Shares closed at $475.07, with a market capitalisation of $13.05 billion.
Medpace Hiring 2026: Junior Data Engineer | Apply now. Medpace Hiring 2026: Medpace is hiring Junior Data Engineers in Bengaluru (2026). Apply for an entry-level Data Engineer role - ideal for freshers and early-career professionals with SQL, Python, ETL knowledge. Competitive pay, growth path, and hybrid work options. Apply now to start your data engineering career. About Medpace: Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,800 people across 42 countries. Job description: * Utilize skills in development areas including data warehousing, business intelligence, and databases (Snowflake, ANSI SQL, SQL Server, T-SQL); * Support programming/software development using Extract, Transform, and Load (ETL) and Extract, Load and Transform (ELT) tools, (dbt, Azure Data Factory, SSIS); * Design, develop, enhance and support business intelligence systems primarily using Microsoft Power BI; * Collect, analyze and document user requirements; * Participate in software validation process through development, review, and/or execution of test plan/cases/scripts; * Create software applications by following software development lifecycle process, which includes requirements gathering, design, development, testing, release, and maintenance; * Communicate with team members regarding projects, development, tools, and procedures; and * Provide end-user support including setup, installation, and maintenance for applications. Skills: * Bachelor's Degree in Computer Science, Data Science, or a related field; * Internship experience in Data or Software Engineering; * Knowledge of developing dimensional data models and awareness of the advantages and limitations of Star Schema and Snowflake schema designs; * Solid ETL development, reporting knowledge based off intricate understanding of business process and measures; * Knowledge of Snowflake cloud data warehouse, Fivetran data integration and dbt transformations is preferred; * Knowledge of Python is preferred; * Knowledge of REST API; * Basic knowledge of SQL Server databases is required; * Knowledge of C#, Azure development is a bonus; and * Excellent analytical, written and oral communication skills. Eligibility criteria. * Qualification: B.E / B.Tech * Work Experience: Freshers / Experienced How to apply for Medpace Hiring 2026? Interested candidates can apply online by clicking the application link below:
Safirstein Law LLC announces that A class action lawsuit has been filed against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). RIDGEWOOD, N.J., June 08, 2026 (GLOBE NEWSWIRE) - RIDGEWOOD, N.J., June 8, 2026 (GLOBE NEWSWIRE) - Safirstein Law LLC announces that a class action lawsuit has been filed on behalf of shareholders against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ:MEDP). | Company: | Medpace Holdings, Inc. | | Ticker: | MEDP | | Lead Plaintiff Deadline: | June 8, 2026 | | Class Period: | from April 22, 2025 through February 9, 2026, inclusive | | Court: | U.S. District Court for the Southern District of Ohio | If you purchased Medpace stock during the class period, and would like more information: | Phone: | 1-844-921-2210 | | Email: | [email protected] | | Website: | https://safirsteinlaw.com/contact | The class action concerns whether Medpace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On February 9, 2026, Medpace released fourth quarter 2025 earnings results, revealing a book-to-bill ratio of 1.04, well below Medpace's guidance. On this news, Medpace's stock price fell $84.30 per share, or 15.9%, to close at $446.05 per share on February 10, 2026. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. About Safirstein Law LLC Safirstein Law LLC focuses its practice on shareholder rights. All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection. Attorney advertising. Prior results do not guarantee a similar outcome. Safirstein Law LLC Peter Safirstein, Esq. Safirstein Law LLC 45 N. Broad Street Ridgewood, NJ 07450 1-844-921-2210 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa SMB Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.